MAM
ENTA icon

Meeder Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Meeder Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.6K Hold
2,025
– – ﹤0.01% 529
2025
Q4 		$31.9K Buy
+2,025
New +$25.7K ﹤0.01% 465
2022
Q4 		– Sell
-90
Closed -$5K – 1150
2022
Q3 		$5K Sell
90
-21
-19% -$1.23K ﹤0.01% 1552
2022
Q2 		$5K Sell
111
-22
-17% -$1.19K ﹤0.01% 1637
2022
Q1 		$9K Buy
+133
New +$8.65K ﹤0.01% 1576
2021
Q4 		– Sell
-106
Closed -$6K – 1523
2021
Q3 		$6K Buy
106
+11
+12% +$544 ﹤0.01% 1852
2021
Q2 		$4K Sell
95
-40
-30% -$1.96K ﹤0.01% 2009
2021
Q1 		$7K Sell
135
-9
-6% -$449 ﹤0.01% 1731
2020
Q4 		$6K Buy
144
+6
+4% +$264 ﹤0.01% 1140
2020
Q3 		$6K Buy
138
+108
+360% +$5.23K ﹤0.01% 1510
2020
Q2 		$2K Buy
+30
New +$1.55K ﹤0.01% 1757
2020
Q1 		– Sell
-127
Closed -$8K – 2370
2019
Q4 		$8K Sell
127
-223
-64% -$13.8K ﹤0.01% 1620
2019
Q3 		$21K Sell
350
-4,008
-92% -$298K ﹤0.01% 1289
2019
Q2 		$368K Buy
4,358
+3,140
+258% +$282K 0.03% 461
2019
Q1 		$117K Sell
1,218
-537
-31% -$48.2K 0.01% 658
2018
Q4 		$124K Sell
1,755
-102
-5% -$7.82K 0.01% 588
2018
Q3 		$159K Sell
1,857
-460
-20% -$46.1K 0.01% 536
2018
Q2 		$269K Buy
2,317
+1,280
+123% +$128K 0.02% 460
2018
Q1 		$85K Sell
1,037
-87
-8% -$6.7K 0.01% 579
2017
Q4 		$66K Buy
1,124
+174
+18% +$8.71K 0.01% 631
2017
Q3 		$45K Buy
950
+795
+513% +$32K ﹤0.01% 699
2017
Q2 		$6K Buy
155
+86
+125% +$2.75K ﹤0.01% 1139
2017
Q1 		$2K Buy
+69
New +$2.15K ﹤0.01% 1361

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Meeder Asset Management's ENTA Position: Q1 2026 in Review

Meeder Asset Management held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 2,025 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #529.

Meeder Asset Management first reported a position in ENTA in Q1 2017 and has held it in 23 quarters since. The position peaked at $368K in Q2 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Meeder Asset Management held 2,025 shares of Enanta Pharmaceuticals worth $25.6K as of Q1 2026.
  • Meeder Asset Management left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #529 holding.
  • Meeder Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2017 and has held it in 23 quarters since.
  • Meeder Asset Management's Enanta Pharmaceuticals position peaked at $368K in Q2 2019.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.